
Jan 23 (Reuters) - Novo Nordisk's NOVOb.CO Wegovy pill tracked 18,410 U.S. prescriptions in the first full week after its launch, IQVIA data shared by an analyst on Friday showed.
Investors are closely watching prescriptions data to see if the Danish drugmaker can press its first-mover advantage against rival Eli Lilly LLY.N in a competitive weight-loss market.
The pill hit 3,071 U.S. prescriptions in the first four days after its launch.
"We note this is tracking ahead of other GLP-1 launches," Guggenheim analysts said in a note.